A Phase 2, Multicenter, Double-Blind, Randomized, Vehicle Controlled Clinical Study to Assess the Safety and Efficacy of IDP 118 in the Treatment of Plaque Psoriasis
Latest Information Update: 09 Mar 2020
At a glance
- Drugs Tazarotene/ulobetasol (Primary) ; Tazarotene; Ulobetasol
- Indications Plaque psoriasis
- Focus Therapeutic Use
- Sponsors Bausch Health Companies; Valeant Pharmaceuticals International
- 04 Mar 2020 Systematic review assessing phase II and phase III clinical trial data (NCT02045277, NCT02785172, NCT02462070, NCT02462122 and NCT02462083) pertaining to efficacy and safety of HP/TAZ combinational topical therapy published in the Annals of Pharmacotherapy
- 13 Jul 2018 According to a Bausch Health Companies media release, Valeant Pharmaceuticals International changed its name to Bausch Health Companies.
- 08 Dec 2014 Status changed from recruiting to completed as reported by ClinicalTrials.gov.